Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease - sprookjes - yvandenbroek - TriplyDB

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

http://www.wikidata.org/entity/Q30054715

about

Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Combination therapy for inflammatory bowel disease Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model?Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.Second Korean guidelines for the management of Crohn's disease.Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.The potential of FimH as a novel therapeutic target for the treatment of Crohn's disease.Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders.Medical versus surgical management of penetrating Crohn's disease: the current situation and future perspectives.New treatment strategies for ulcerative colitis.Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.Optimizing pharmacologic management of inflammatory bowel disease.Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis.Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease.Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.Enrichment of IL-17A+ IFN-γ+ and IL-22+ IFN-γ+ T cell subsets is associated with reduction of NKp44+ ILC3s in the terminal ileum of Crohn's disease patients.Positioning ustekinumab in Crohn's disease: from clinical evidence to clinical practice.A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies.The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.Crohn's disease for the general physician: management.Recent advances in gut immunology.The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease.Ustekinumab: A Review in Moderate to Severe Crohn's Disease.The dichotomous nature of T helper 17 cells.Frontiers in Drug Research and Development for Inflammatory Bowel Disease.Infection risk with biologic therapy in patients with inflammatory bowel disease.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.Management of patients with inflammatory bowel disease and spondyloarthritis.Pneumocystis jirovecii Pneumonia in Pediatric Inflammatory Bowel Disease: A Case Report and Literature Review.Hair Growth in Two Alopecia Patients after Fecal Microbiota Transplant.A role for oncostatin M in inflammatory bowel disease.Anti-NKG2D mAb: A New Treatment for Crohn's Disease?Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease.

P2860

Q28067631-27519B86-8A65-443C-9F71-9C87997647D1 Q30235581-C821D3F4-D15C-467E-B517-6ED09CB91E74 Q33646452-96C16BE0-63FE-4963-A8BC-0B981A5175FB Q33711741-0A3CE118-CD7A-4EEA-92F9-663143E33606 Q33819478-62B115D9-E3FE-4DC9-9DCD-AF91B3F57EBC Q36203845-6C721634-0CBB-45DA-81D0-19AB2DB63175 Q36407822-F4DFDA26-D2D5-48A1-8176-2C73FAA20D57 Q37662498-AAF49C37-1F07-4C6A-9753-B029B557C3F0 Q38645111-66A69371-456C-4682-AA06-EE42EF2EB8CF Q38648792-103AE9DC-4585-45B5-8CB5-E052674128F6 Q38665573-7DC3B80B-54DE-4DF5-BE5C-DC782288E617 Q38668874-000AF24F-5BEC-44BB-9072-96B3380882D8 Q38670811-37E3DDFB-C5DA-4464-964A-14BE60FEE04C Q38681918-C7880D87-105F-420E-B6B0-B36226662B00 Q38687407-2B710846-115E-456F-B5ED-33D6591233C3 Q38702997-A37A9376-089A-4A8D-93BB-F7BF0E5196F8 Q38726458-60567776-8F08-4FA4-B036-1E3C28CD8A13 Q38735146-667661AC-DA19-48AF-BF79-6D7EB400AE64 Q38741014-47E5FCA7-3867-479D-9196-E5E95528AA6A Q38748380-C2B4590F-972A-485D-A1A3-CA09AD3C25B8 Q38749257-64EA0915-8B92-4BD6-8B5E-38E18434A583 Q38750548-C05A66DF-343E-488C-A771-0A3A2E281F2D Q38761961-3382A68F-208F-4512-B02C-42399A078393 Q38805575-EB155A29-E932-4C69-A7F0-6ED0B20DE4C3 Q39122303-7A05DE1F-E9E8-4047-A00A-862F5A3E776A Q39215821-885C6880-E686-4FE3-9FB0-CB0016268DB2 Q39233355-B00A4598-E141-411C-A89D-234983651249 Q39320474-42F73861-2812-4DF0-A1F0-054DD8E56DFB Q39337496-1AE7B3AF-4A8D-484D-B395-9C1C9B4300F8 Q39424463-B9F1FEFA-4A4C-4E6C-905B-DF8A1F1B3B52 Q39429997-6F1ECB37-BB7F-4DA0-9958-903E30FA3841 Q39435409-E991A42B-D4E7-4BD5-8BF2-48F89B2B9999 Q40054186-38FFB277-9FE8-4575-B070-FD27EFB30ABD Q40100993-8F288CC5-A73C-4BED-9A57-6090E37F7118 Q41044153-55F0FE3E-BAB6-43E5-A094-40432CD51CE2 Q41129532-A17F8D3C-6014-4C79-9D94-55DDFA3B73B0 Q41660377-3C07C884-DA7A-410D-A330-19E825BAACB5 Q41846031-B6E1298D-CF40-462E-9508-725E5CFF4A21 Q44581309-D1B6CAE8-00E3-405C-9C88-0A7CC375482D Q46027208-78BB4537-F78B-411C-8B09-6E18A7970131

P2860

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

http://www.wikidata.org/entity/Q30054715

description

2016 nî lūn-bûn

@nan

2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

@ast

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

@en

type

label

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

@ast

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

@en

prefLabel

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

@ast

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

@en

P1433

Q30054715-F1309FBC-9BFA-421B-AA70-B4BC502182FA

P1476

Q30054715-640186A9-1E0E-4A1B-B762-32F884D8BDE2

P2093

Q30054715-015B60A4-4CD9-4AEF-B655-AD8CE93237E8

Q30054715-13ED363F-5BB6-409F-BBFF-CF2CDA1E6953

Q30054715-2D29216A-9811-41BF-B677-FE54F0412F92

Q30054715-3412BD87-BC2D-4167-A203-6255BC6550FE

Q30054715-40334C91-6E47-406E-AC15-5863DBF447F9

Q30054715-459E75CE-809A-4D69-ABDE-0E6D8490512D

Q30054715-51AA514A-7B7D-49A8-8297-025C809EFD43

Q30054715-537F7E01-EEC9-4891-8C9E-8DA6F0F9F63F

Q30054715-55FE2B04-F816-46B9-81E6-1655E985158C

Q30054715-6EA46D1C-7137-40E3-916E-9DF52C3C892A

P304

Q30054715-E2937194-8FF8-4CF6-AA82-23539535FE11

P31

Q30054715-AC30EBAA-7A12-4D1A-B7BE-5834BC143E0C

P356

Q30054715-5E621430-5C1F-46F5-86FE-2C5A52602096

P407

Q30054715-95F94169-5BBD-4CDB-89D3-697E81DE2CB9

P433

Q30054715-3701422E-409A-4224-A0FC-CCEA978F18BF

P478

Q30054715-180BFC1E-8A25-4172-B40C-201A7F1C4C4F

P50

Q30054715-353869AB-04B1-449E-8B86-11D3E7BD8858

Q30054715-408F0EB4-31AA-480B-962E-15D7EFD959D2

Q30054715-481CB5A5-5B27-43F6-8C87-B22DEF950C2D

Q30054715-8B5DD96C-22D8-4E1A-A0D6-132039BD406A

Q30054715-E17C4367-9BB8-43B8-A6E0-71C216E017ED

Q30054715-EFF09B84-6B90-48BB-A9E3-FECCB4BC0FAD

P577

Q30054715-B16545F6-C291-4E13-A0CF-A812A580E142

P698

Q30054715-76C31D03-6E00-474C-A5C8-864B1BE0F0A5

P356

P1433

The New England Journal of Medicine

P1476

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

@en

P2093

Bruce A. Salzberg

http://www.w3.org/2001/XMLSchema#string

Bruce E. Sands

http://www.w3.org/2001/XMLSchema#string

Christopher Gasink

http://www.w3.org/2001/XMLSchema#string

Douglas Jacobstein

http://www.w3.org/2001/XMLSchema#string

Edward V. Loftus

http://www.w3.org/2001/XMLSchema#string

Jewel Johanns

http://www.w3.org/2001/XMLSchema#string

Joshua R. Friedman

http://www.w3.org/2001/XMLSchema#string

Levinus A. Dieleman

http://www.w3.org/2001/XMLSchema#string

Long-Long Gao

http://www.w3.org/2001/XMLSchema#string

Marion A. Blank

http://www.w3.org/2001/XMLSchema#string

P304

1946-1960

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1602773

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Frédéric Colombel

Pierre Desreumaux

William Jeffery Sandborn

Brian G. Feagan

P577

2016-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27959607

http://www.w3.org/2001/XMLSchema#string